首页> 美国卫生研究院文献>Journal of Aerosol Medicine and Pulmonary Drug Delivery >In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™)
【2h】

In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™)

机译:ELLIPTA®干粉吸入器的体外给药性能(使用哮喘和COPD患者的吸入曲线与电子肺(eLung™)复制)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: To evaluate the in vitro dose delivery characteristics of approved asthma and chronic obstructive pulmonary disease (COPD) therapies delivered via the ELLIPTA® dry powder inhaler across inhalation endpoints representative of the target patient population, using the Electronic Lung (eLung™) to replicate inhaler-specific patient inhalation profiles that were previously recorded in vivo.>Methods: Selected profiles, representative of the range of inhalation endpoints achieved by patients with all severities of asthma and COPD, were replicated using the eLung breathing simulator in conjunction with an oropharyngeal cast. A Next Generation Impactor was coupled to the eLung to determine the aerodynamic particle size distribution of the ex-throat dose (ETD) of asthma and COPD therapies delivered via the ELLIPTA inhaler. Delivered dose (DD), ETD, and fine particle dose (FPD; defined as a mass of active substance less than 5 μm) were determined for fluticasone furoate (FF)/vilanterol (VI) 100/25 μg and 200/25 μg (asthma and COPD), umeclidinium (UMEC)/VI 62.5/25 μg (COPD only), FF 100 μg and 200μg monotherapy (asthma only), and UMEC 62.5 μg monotherapy (COPD only).>Results: Inhalation profiles replicated by eLung covered a wide range of peak inspiratory flow rates (41.6–136.9 L/min), pressure drops (1.2–13.8 kPa), and inhaled volumes through the inhaler (0.7–4.2L). DD was consistent across the range of patient representative inhalation parameters for all components (FF, VI, and UMEC) of each therapy assessed; although ETD and FPD were also generally consistent, some small variation was observed. Dose delivery was consistent for each of the components, whether delivered as mono- or combination therapy.>Conclusions: The in vitro performance of the ELLIPTA inhaler has been demonstrated for the delivery of FF/VI, UMEC/VI, FF monotherapy, and UMEC monotherapy. Across a range of inspiratory profiles, DD was consistent, while ETD and FPD showed little flow dependency.
机译:>背景:为了评估通过ELLIPTA ®干粉吸入器提供的已批准的哮喘和慢性阻塞性肺疾病(COPD)疗法的体外剂量传递特性,这些吸入剂代表了目标人群,使用电子肺(eLung™)复制先前在体内记录的特定于吸入器的患者吸入曲线。>方法:选定的曲线,代表患有以下疾病的患者达到的吸入终点范围使用eLung呼吸模拟器和口咽模型复制了所有严重程度的哮喘和COPD。下一代撞击器与eLung相连,以确定通过ELLIPTA吸入器进行的哮喘和COPD治疗的咽喉外剂量(ETD)的空气动力学粒径分布。测定糠酸氟替卡松(FF)/维兰特罗(VI)100 /25μg和200 /25μg的递送剂量(DD),ETD和细颗粒剂量(FPD;定义为小于5μm的活性物质的质量)(哮喘和COPD),umeclidinium(UMEC)/ VI 62.5 /25μg(仅适用于COPD),FF100μg和200μgFF(仅适用于哮喘)和UMEC62.5μμg单一疗法(仅适用于COPD)。>结果: eLung复制的吸入曲线涵盖了大范围的吸气峰值流速(41.6–136.9 L / min),压降(1.2–13.8 kPa)和通过吸入器的吸入量(0.7–4.2L)。在评估的每种疗法的所有成分(FF,VI和UMEC)的患者代表性吸入参数范围内,DD均一致。尽管ETD和FPD通常也一致,但是观察到一些小的变化。无论是单药治疗还是联合治疗,每种成分的剂量输送都是一致的。>结论:已证明ELLIPTA吸入器的体外性能可输送FF / VI,UMEC / VI ,FF单药和UMEC单药。在各种吸气曲线中,DD是一致的,而ETD和FPD几乎没有血流依赖性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号